SPONSOR
BeOne Medicines
Total Trials
3
Recruiting
3
Phases
Phase 1, Phase 3
BeOne Medicines is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including Skin Diseases, Solid Tumors, Advanced Solid Tumor, CLL.
The trial portfolio spans Phase 1, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — BeOne Medicines
How many clinical trials has BeOne Medicines sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by BeOne Medicines, of which 3 are actively recruiting participants. These trials cover conditions including Skin Diseases, Solid Tumors, Advanced Solid Tumor. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does BeOne Medicines research focus on?
BeOne Medicines clinical trials span Skin Diseases, Solid Tumors, Advanced Solid Tumor, CLL, Chronic Lymphocytic Leukemia. The research pipeline includes Phase 1, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a BeOne Medicines clinical trial?
To participate in a BeOne Medicines trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all BeOne Medicines trials with current recruitment status updated daily.
Clinical Trials by BeOne Medicines
NCT07412691 Phase 1
Recruiting
A Study to Evaluate the Safety of BG-A3004 in Healthy Participants and Patients With Immune-Mediated Skin Diseases
Skin Diseases
NCT07181681 Phase 1
Recruiting
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
Solid Tumors
NCT06846671 Phase 3
Recruiting
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
CLL
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology